Business news for the stock market

Medigene AG: Medigene revises collaboration with Mitsui Norin

Planegg (pta035/23.03.2017/14:20 UTC+1) Medigene AG (FWB: MDG1, Prime Standard, TecDAX) today announced a new contractual arrangement with Mitsui Norin Co. Ltd, regarding its drug Veregen®.

Medigene had contracted Mitsui Norin since 2005 for manufacturing and supplying the active pharmaceutical ingredient (API) of Veregen®. Based on new supporting data regarding a longer shelf life of the API, Medigene now estimates that there is a sufficiently high stockpile to market the drug for several years - well beyond the maximum patent term covering the product. For this reason, the current manufacturing and supply agreement has been mutually terminated as of 31 March 2017.

The previous agreement has been replaced by a new license agreement covering the drug master file (DMF) for Veregen®. The DMF, for which Medigene has now acquired an exclusive license from Mitsui Norin, is vital for admission to existing and new potential markets for Veregen®, as well as for future product sales by distribution partners. The term of the license is not limited by the expiration of the patents. In addition, appropriate steps to resume production of the API can be initiated at any time, as needed.

As a part of the arrangement to terminate the existing manufacturing and supply agreement, Medigene has agreed to a one-time payment of USD 1.75 million to Mitsui Norin. This amount is offset by Medigene's annual savings resulting from the elimination of an existing annual minimum purchase requirement. An additional payment to Mitsui Norin for up to USD 0.5 million to reimburse the costs of ending production is also expected in the course of 2017. No further financial details regarding the new license agreement were disclosed.

Commenting, Dave Lemus, COO of Medigene, said, "We are pleased with today's announcement as it relates to the new direction of our relationship with Mitsui Norin. Moreover, the new agreement allows us maximum flexibility to manage Medigene's supply chain supporting Veregen®, especially as we consider our strategic alternatives for this product going forward."

With the realignment of Medigene's strategic focus towards immunotherapies in 2014, Veregen® is not considered to be part of the core business of the company and is currently marketed by various distribution partners around the world.


More on Veregen®: The drug, which is used to treat genital warts by patients exposed to human papillomavirus types 6 and 11, is approved in 21 countries and marketed worldwide by a range of distribution partners. In 2015 Medigene generated revenue of approximately Eur3 m with sales of Veregen®. More information on Veregen® can be found at

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in clinical and pre-clinical development.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

In case you no longer wish to receive any information about Medigene, please inform us by e-mail ( We will then delete your address from our distribution list.


Emitter: Medigene AG
Lochhammer Straße 11
82152 Planegg
Contact Person: Julia Hofmann, Head of Public & Investor Relations
Phone: +49 89 200033-3301
ISIN(s): DE000A1X3W00 (Share)
Stock Exchange(s): Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate